Gregory Smith, LISW-CPS Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 161 Landmark Dr, Taylors, SC 29687 Phone: 864-244-0154 Fax: 864-609-5003 |
Linda Jo Griffin, LISW-CP, CAC-II Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 161 Landmark Dr, Taylors, SC 29687 Phone: 864-244-0154 |
Mrs. Rochelle Mia Hoffman, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 161 Landmark Dr, Taylors, SC 29687 Phone: 864-244-0154 Fax: 864-609-5003 |
Courtnie Merrill-perry Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 8 Casting Ct, Taylors, SC 29687 Phone: 801-625-3700 |
Jennifer Lynn Strawn Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 310 Angie Dr, Taylors, SC 29687 Phone: 864-230-6723 |
Mrs. Redonia M Thomas, ACSW, LISW-CP Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 302 W Main St, Taylors, SC 29687 Phone: 864-244-1007 |
Mrs. Beverly Anne Wagner, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 161 Landmark Dr, Taylors, SC 29687 Phone: 864-244-0154 Fax: 864-609-5003 |
News Archive
The COVID-19 pandemic is threatening to come back in greater intensity during the winter and fall. Faced with this threat, vaccine development efforts are entering a phase of renewed focus, attempting to identify antigens capable of eliciting protective levels of neutralizing antibodies. A new study published on the preprint server bioRxiv* in October 2020 reports on a novel mRNA vaccine candidate's performance in two animal models.
A new Boston University School of Public Health study is the first-ever population-based study of cancer prevalence in transgender people, estimating 62,530 of the nearly 17 million cancer survivors in the U.S. are transgender.
Scientists have identified a genetic variant which increases susceptibility to tuberculosis (TB) in African populations using a technique known as a genome-wide association (GWA) study. This is the first novel disease variant to be identified using this technique in Africans and demonstrates that such studies are viable in African populations, which have a high degree of genetic diversity.
Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
› Verified 6 days ago